公开(公告)号：US20240197821A1

公开(公告)日：2024-06-20

申请号：US18495355

申请日：2023-10-26

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) ,  Université Paris-Sud

发明人： Joël DORE ,  Jamila FAIVRE ,  Nicolas MONIAUX ,  Christian BRECHOT ,  Marion DARNAUD

IPC分类号： A61K38/17 ,  A23L33/19

CPC分类号： A61K38/1709 ,  A23L33/19

摘要： The present disclosure concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions including the polypeptide, and their use. The disclosure shows that increasing concentration of the hReg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. The Reg3α polypeptide may be used for preventing or treating microbiota-related diseases and/or disorders, including inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders, and the prevention and treatment methods may also include transferring to said patient fecal microbiota from a human or animal expressing the Reg3α polypeptide.

公开(公告)号：US20220233639A1

公开(公告)日：2022-07-28

申请号：US17573913

申请日：2022-01-12

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) ,  Université Paris-Sud

发明人： Joël DORE ,  Jamila FAIVRE ,  Nicolas MONIAUX ,  Christian BRECHOT ,  Marion DARNAUD

IPC分类号： A61K38/17 ,  A23L33/19

摘要： The invention concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide, and their use. The inventors showed that increasing concentration of the hReg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3α exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and the ROS scavenging activity, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that hReg3α-transgenic mice were better able to resist DSS-induced colitis after antibiotherapy. The Reg3α polypeptide may be used for preventing or treating microbiota-related diseases and/or disorders, including inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders.

公开(公告)号：US20210093694A1

公开(公告)日：2021-04-01

申请号：US16630252

申请日：2018-07-13

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) ,  Université Paris-Sud

发明人： Joël DORE ,  Jamila FAIVRE ,  Nicolas MONIAUX ,  Christian BRECHOT ,  Marion DARNAUD

IPC分类号： A61K38/17 ,  A23L33/19

摘要： The invention concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3α exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3α-transgenic mice resist better to DSS-induced colitis after antibiotherapy. Thus, the invention concerns a Reg3α polypeptide for use in the protection of oxygen sensitive gram-positive bacteria, notably the Ruminococcaceae, such as Faecalibacterium prausnitzii, and/or the Lachnospiraceae, such as Roseburia intestinalis; pharmaceutical compositions comprising the polypeptide and their use; and the use of this polypeptide for promoting ex vivo growth of oxygen sensitive gram-positive bacteria. The Reg3α polypeptide may be used for preventing or treating microbiota-related disease and/or disorder, particularly selected from inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders.